anti-PD-L1 CSR T-cell therapy (Marino Biotechnology)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-PD-L1 CSR T-cell therapy (Marino Biotechnology)
Drug Alias Nameanti-PD-L1 CAR T-cell therapy (Marino Biotechnology)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed death-ligand 1 modulators
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsGlioblastomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Marino Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Marino Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A